Abstract 3769
Background
Pembrolizumab monotherapy showed significantly longer progression-free survival and overall survival (OS), and fewer treatment-related adverse events (AEs) compared to chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC) with PD-L1 positive tumors in the first-line setting (KEYNOTE-024 (KN024)) and in those previously treated (KEYNOTE-010 (KN010)). The objective of this analysis is to assess the benefit-risk of pembrolizumab in terms of quality-adjusted survival amongst patients in these trials.
Methods
The Quality-adjusted Time without Symptoms of disease progression or Toxicity of treatment (Q-TWiST) analysis was used to compare the trial arms. Survival time of each patient was partitioned into three health states: with toxicity before disease progression, without toxicity before disease progression, and disease progression until death. Toxicities considered were grade 3+ AEs. Mean utility scores for the three health states were estimated using EQ-5D-3L data collected in the trials. Q-TWiST was calculated as the utility-weighted sum of the mean health state durations. KN024 and KN010 have undergone several interim analyses. Data from each of these analyses were examined. The published criterion [Revicki 2006] for a ‘clearly clinically important’ improvement in Q-TWiST is 15% of mean OS in a study.
Results
Based on the most recent analysis of KN024 from July 10, 2017 and KN010 from March 24, 2017, patients randomized to pembrolizumab had 3.25 months (about 20% of mean OS) greater Q-TWiST (P < 0.001) compared to those randomized to platinum-based chemotherapy in KN024, and 3.11 months (about 25% of mean OS) greater Q-TWiST (P < 0.001) compared to docetaxel in KN010. Results across KN024 and KN010 trial analyses showed an increase in trend for the Q-TWiST improvement of pembrolizumab over time.
Conclusions
Pembrolizumab showed statistically significant and clinically meaningful improvement in quality-adjusted survival using the Q-TWiST analysis compared to chemotherapy in mNSCLC in both previously untreated and treated patients. The benefits continued to accrue over the trial follow-up period with extended survival.
Clinical trial identification
Legal entity responsible for the study
Merck & Co. Inc.
Funding
Merck & Co. Inc.
Editorial Acknowledgement
Disclosure
M. Huang, M.C. Pietanza, A. Samkari, J. Pellissier, T. Burke, S. Chandwani, F. Kong: Employee: Merck & Co., Inc. A.S. Pickard: Consulting fees: Merck, Eli Lilly, Bristol-Myers Squibb, Novartis/Avexis.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract